<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01129271</url>
  </required_header>
  <id_info>
    <org_study_id>ALI11209</org_study_id>
    <nct_id>NCT01129271</nct_id>
  </id_info>
  <brief_title>Food Effect Study on Pharmacodynamic and Bioavailability of Clopidogrel 300/75 mg in Healthy Subjects</brief_title>
  <official_title>A Randomized, Placebo-controlled, Two-sequence, Two-period Crossover Study, to Investigate a Potential Food Effect on the Pharmacodynamic and Bioavailability of Repeated Oral Doses of Clopidogrel (300 mg Loading Dose Followed by 75 mg/Day) in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

        -  Investigate the potential food effect on Adenosine diphosphate(ADP)-induced platelet
           aggregation after 5-day repeated doses of clopidogrel (300 mg loading dose followed by 4
           days 75 mg/day) in healthy subjects

      Secondary objectives are to investigate the potential food effect on:

        -  ADP-induced platelet aggregation after 300 mg loading dose of clopidogrel

        -  Pharmacokinetic profiles of clopidogrel and its active metabolite after 5-day repeated
           doses of clopidogrel
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total duration per subject is 8-9 weeks broken down as follows:

        -  Screening: 2 to 21 days before the first dosing

        -  Fed period: 7 days including 5 treatment days

        -  Washout: at least 14 days after last dosing

        -  Fasted period: 7 days including 5 treatment days

        -  End of study: 7 to 10 days after the last dosing
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum platelet aggregation intensity (MAI) induced by Adenosine diphosphate (ADP) 5µM after 5 days treatment</measure>
    <time_frame>Day 5 of each period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum platelet aggregation intensity (MAI) induced by ADP 5µM after loading dose and high fat breakfast</measure>
    <time_frame>6 hours and 24 hours after first dosing of each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clopidogrel pharmacokinetic parameters (maximum plasma concentration (Cmax) and area under the plasma concentration curve (AUC0-24)) after 5 days treatment</measure>
    <time_frame>up to 24 hours postdose on Day 5 for each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clopidogrel active metabolite pharmacokinetic parameters (Cmax and AUC0-24) after 5 days treatment</measure>
    <time_frame>up to 24 hours postdose on Day 5 for each period</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group clopidogrel fed - fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1:
Day 1: clopidogrel 300 mg loading dose with high fat breakfast
Day 2 to Day 5: clopidogrel 75 mg/day with standard breakfast, once daily
Period 2:
Day 1: clopidogrel 300 mg loading dose under fasted conditions
Day 2 to Day 5: clopidogrel 75 mg/day under fasted conditions, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group placebo fed - fasting</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Period 1:
Day 1: placebo loading dose with high fat breakfast
Day 2 to Day 5: placebo with standard breakfast, once daily
Period 2:
Day 1: placebo loading dose under fasted conditions
Day 2 to Day 5: placebo under fasted conditions, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group clopidogrel fasting - fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1:
Day 1: clopidogrel 300 mg loading dose under fasted conditions
Day 2 to Day 5: clopidogrel 75 mg/day under fasted conditions, once daily
Period 2:
Day 1: clopidogrel 300 mg loading dose with high fat breakfast
Day 2 to Day 5: clopidogrel 75 mg/day with standard breakfast, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group placebo fasting -fed</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Period 1:
Day 1: placebo loading dose under fasted conditions
Day 2 to Day 5: placebo in fasted conditions, once daily
Period 2:
Day 1: placebo loading dose with high fat breakfast
Day 2 to Day 5: placebo with standard breakfast, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>Pharmaceutical form: tablet
Route of administration: oral</description>
    <arm_group_label>Group clopidogrel fed - fasting</arm_group_label>
    <arm_group_label>Group clopidogrel fasting - fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>Pharmaceutical form: tablet
Route of administration: oral</description>
    <arm_group_label>Group placebo fed - fasting</arm_group_label>
    <arm_group_label>group placebo fasting -fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy male subjects:

          -  as determined by medical history, physical examination including vital signs and
             clinical laboratory tests

          -  with a body weight between 50kg and 95 kg and a Body Mass Index (BMI) between 18 and
             30 kg/m2

        Exclusion Criteria:

          -  Evidence of inherited disorder of coagulation/hemostasis functions

          -  Smoking more than 5 cigarettes or equivalent per day

          -  Abnormal hemostasis screen

          -  Any contraindication to clopidogrel

          -  Unability to abstain from intake of any drug affecting haemostasis throughout the
             whole study duration

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>International Clinical Development Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hurbin F, Boulenc X, Daskalakis N, Farenc C, Taylor T, Bonneau D, Lacreta F, Cheng S, Sultan E. Clopidogrel pharmacodynamics and pharmacokinetics in the fed and fasted state: a randomized crossover study of healthy men. J Clin Pharmacol. 2012 Oct;52(10):1506-15. Epub 2011 Nov 29.</citation>
    <PMID>22128201</PMID>
  </results_reference>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2010</study_first_submitted>
  <study_first_submitted_qc>May 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2010</study_first_posted>
  <last_update_submitted>December 14, 2011</last_update_submitted>
  <last_update_submitted_qc>December 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

